Tonghua Dongbao Pharmaceutical
3
12M
3
0.08
2
- Areas of investment
Summary
The fund was located in Asia if to be more exact in China. The leading representative office of defined Corporate Investor is situated in the Tonghua.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2017. The fund is constantly included in less than 2 investment rounds annually.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Medical. Among the various public portfolio startups of the fund, we may underline POCTech Corporation For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Tonghua Dongbao Pharmaceutical, startups are often financed by LenoMed Medical, Legend Capital. The meaningful sponsors for the fund in investment in the same round are Tasly Great Health Industry Fund, Legend Capital, BioVenture.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 2
- Rounds per year
- 0.08
- Investments by industry
- Medical (3)
- Biotechnology (2)
- Sales (1)
- Health Care (1)
- Medical Device (1) Show 1 more
- Investments by region
-
- China (3)
- Peak activity year
- 2015
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Group Appearance index
- 0.33
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Junhemeng Biopharmaceutical | 08 May 2024 | Biotechnology, Medical, Biopharma | Early Stage Venture | 15M | Hangzhou, Zhejiang, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.